Going overseas is an important way for innovative pharmaceutical companies to explore new business growth points, and it is an inevitable trend
for innovative biopharmaceutical companies to go overseas.
Nowadays, more and more pharmaceutical companies have entered the international market, and the European market has become the target
of more and more pharmaceutical companies.
For example, on the evening of November 30, Fosun Pharma announced that Gland Pharma and its holding subsidiary Gland Intl.
intend to purchase 99.
84% of the equity of Cenexi Group, a French CDMO company, and provide shareholders' loans to it, with the total transfer consideration and shareholder borrowing not exceeding 2.
1 euros, or about RMB 1.
55 billion
.
Regarding the acquisition, Fosun Pharma said that Cenexi Group's CDMO business model is in line
with Gland Pharma's long-term development plan.
After the completion of this transaction, Gland Pharma will expand its product and service supply capabilities in the European market by acquiring local production bases in Europe.
At the same time, it is conducive to enhancing the development, manufacturing and supply capabilities of Gland Pharma's complex formulations and biologics, and enriching its customer resources
.
The data shows that under the global market layout, Fosun Pharma achieved overseas revenue of 7.
592 billion yuan in the first half of 2022, a year-on-year increase of 46.
06%, and the proportion of revenue also increased to 35.
58%.
According to combing, since 2022, there have been many
cases of Chinese pharmaceutical companies entering the European market.
In addition to Fosun Pharma, many pharmaceutical companies such as Porton, BeiGene, and Junshi Biologics also announced that they have "broken through" the European market
.
For example, Porton announced on the evening of August 2 that in order to further expand the global operation layout, the company plans to build a R&D and production base in Slovenia, focusing on GMP intermediates and API production process development, analytical method development and kilogram to 100kg preparation services
required from preclinical to clinical stage to the full life cycle of drug launch 。 The investment project intends to lease the site of Lek (a subsidiary of Novartis) at Kolodvorska cesta 27, 1234 Menges, Slovenia, and invest 50 million euros (equivalent to about 350 million yuan) to build a R&D and production base, which is expected to be put into operation in
September 2024.
Porton said that the process development and production base that the company plans to build in Slovenia will become the company's first R&D and production base
in Europe.
Slovenia's R&D and production base will effectively cooperate with the company's existing business development and R&D bases in Europe and the United States to promote the smooth implementation
of the company's internationalization strategy.
At the same time, the establishment of a R&D and production platform in Slovenia will help the company introduce experienced talents in the CDMO industry in Europe and enhance the company's competitiveness
.
It is reported that the planned construction of this investment project includes process development laboratory, kilogram laboratory, process safety laboratory, analytical research laboratory and pilot plant
.
After the site is put into use, the company's overseas API process development and production services will be expanded from kilograms to 100 kilograms
.
It is reported that BeiGene has also begun to seek to "break through" the European market
this year.
For example, on April 6, BeiGene announced that the European Medicines Agency has accepted marketing authorization for tislelizumab for two cancers, one for the treatment of esophageal squamous cell carcinoma and one for non-small cell lung cancer
.
Recently, it has continuously released an announcement
on the listing of its product zebratinib capsules in the EU.
In addition, on November 24, Junshi Biologics also announced that the company has recently submitted a marketing authorization application
for the anti-PD-1 monoclonal antibody drug teripulimab to the UK Medicines and Healthcare Products Agency (MHRA).
The indications declared this time are: 1) teripulimab combined with cisplatin and gemcitabine for first-line treatment in patients with locally recurrent or metastatic nasopharyngeal carcinoma (NPC); 2) Teripulimab in combination with paclitaxel and cisplatin for first-line treatment
in patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Previously, Junshi Biologics has submitted marketing authorization applications
for these two indications to the European Medicines Agency (EMA).
Analysts said that in recent years, with the introduction and landing of a series of policies to encourage the research and development of new drugs, the innovation vitality of China's biomedical industry has been continuously improved, playing an increasingly important role
in the global pharmaceutical innovation map.
At the same time, the domestic innovative drug market competition is becoming increasingly fierce, in order to get out of the "involution", actively seek a way to break the situation, "going to sea" has become an important choice for pharmaceutical companies to find new market opportunities, and domestic pharmaceutical companies in the "going to sea", in addition to the United States, the European market has gradually become their "dream place"
to explore new opportunities.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
